Bimatoprost/timolol: a review of its use in glaucoma and ocular hypertension (Q37394089)

20 August 2017

1 reference

title

Bimatoprost/timolol: a review of its use in glaucoma and ocular hypertension (English)

1 reference

20 August 2017

arterial hypertension

0 references

1

Monique P Curran

1 reference

20 August 2017

Jennifer S Orman

2

1 reference

20 August 2017

1 January 2009

1 reference

20 August 2017

1 reference

20 August 2017

26

1 reference

20 August 2017

2

1 reference

20 August 2017

169-184

1 reference

https://scigraph.springernature.com/pub.10.2165/0002512-200926020-00008

20 August 2017

0 references

cites work

Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial

1 reference

https://api.crossref.org/works/10.2165%2F0002512-200926020-00008

Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0002512-200926020-00008

One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0002512-200926020-00008

Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0002512-200926020-00008

The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0002512-200926020-00008

The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0002512-200926020-00008

Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0002512-200926020-00008

The influence of prior therapy on the success of trabeculectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0002512-200926020-00008

Pharmacological considerations in the treatment of glaucoma

21 January 2018

1 reference

12 December 2020

Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group

1 reference

12 December 2020

The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group

1 reference

12 December 2020

Management of glaucoma: focus on pharmacological therapy

1 reference

12 December 2020

Comparison of intraocular pressure lowering efficacy of bimatoprost / timolol fixed combination and other glaucoma medications in the treatment of glaucoma

1 reference

12 December 2020

A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glauc

1 reference

12 December 2020

Medical management of glaucoma

1 reference

12 December 2020

Compliance in patients prescribed eyedrops for glaucoma

1 reference

12 December 2020

The number of people with glaucoma worldwide in 2010 and 2020

1 reference

12 December 2020

Current status of prostaglandin therapy: latanoprost and unoprostone

1 reference

12 December 2020

Effects of glaucoma drugs on ocular hemodynamics in normal tension glaucoma: a randomized trial comparing bimatoprost and latanoprost with dorzolamide [ISRCTN18873428]

1 reference

12 December 2020

Current management of glaucoma

1 reference

12 December 2020

1 reference

12 December 2020

Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops

1 reference

12 December 2020

Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma

1 reference

12 December 2020

Current management of glaucoma and the need for complete therapy.

1 reference

12 December 2020

The pharmacology of bimatoprost (Lumigan).

1 reference

12 December 2020

Prostamides (prostaglandin-ethanolamides) and their pharmacology

1 reference

12 December 2020

A cost-effectiveness analysis of fixed-combination therapies in patients with open-angle glaucoma: a European perspective

1 reference

12 December 2020

Managed care and the impact of glaucoma

1 reference

12 December 2020

Global data on visual impairment in the year 2002

1 reference

12 December 2020

Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy: a multicenter, randomized, investigator-masked, clinical study

1 reference

12 December 2020

Studies on the mechanism of action of timolol and on the effects of suppression and redirection of aqueous flow on outflow facility

1 reference

12 December 2020

Use of fixed-dose combination drugs for the treatment of glaucoma

1 reference

12 December 2020

Fixed-combination and emerging glaucoma therapies

1 reference

12 December 2020

1 reference

12 December 2020

Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure

1 reference

12 December 2020

A comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucoma

1 reference

12 December 2020

The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators

1 reference

12 December 2020

Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension

1 reference

12 December 2020

Penetration of timolol eye drops into human aqueous humour

1 reference

12 December 2020

Bimatoprost/timolol fixed combination vs latanoprost/timolol fixed combination in open-angle glaucoma patients

1 reference

12 December 2020

A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension

1 reference

12 December 2020

Bimatoprost: a pharmacoeconomic review of its use in open-angle glaucoma and ocular hypertension

1 reference

12 December 2020

Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24-hour heart rate response in patients on treatment for glaucoma

1 reference

12 December 2020

Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study

1 reference

12 December 2020

A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components

1 reference

12 December 2020

Effect of bimatoprost on ocular circulation in patients with open-angle glaucoma or ocular hypertension

1 reference

12 December 2020

Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension

1 reference

12 December 2020

Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery

1 reference

12 December 2020

Fixed combinations of topical glaucoma medications

1 reference

12 December 2020

Clinical guidelines for the treatment of glaucoma.

1 reference

12 December 2020

Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma

1 reference

12 December 2020

Latanoprost : an update of its use in glaucoma and ocular hypertension

1 reference

12 December 2020

10.2165/0002512-200926020-00008

Identifiers

DOI

1 reference

PubMed ID

19220073

Dimensions Publication ID

20 August 2017

0 references

1 reference

PubMed ID

19220073